Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

PARP inhibitors (PARPi) have drastically changed the treatment landscape of advanced
ovarian tumors with BRCA mutations. However, the impact of this class of inhibitors in …

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that drives the
generation of myeloid cell subsets including neutrophils, monocytes, macrophages, and …

Resistance to anticancer therapies includes primary resistance, usually related to lack of
target dependency or presence of additional targets, and secondary resistance, mostly …

Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple
tumours. However, only a few patients respond to ICIs, which has generated considerable …

Inflammation, especially chronic inflammation, plays a pivotal role in tumorigenesis and
metastasis through various mechanisms and is now recognized as a hallmark of cancer and …

Metastatic progression combined with non-responsiveness towards systemic therapy often
shapes the course of disease for cancer patients and commonly determines its lethal …

Compared with conventional chemotherapy and targeted therapy, immunotherapy has
changed the treatment prospects of various solid tumors and has recently become the main …

The past few decades have witnessed the rise of immunotherapy for Gastrointestinal (GI)
tract cancers. The role of immune checkpoint inhibitors (ICIs), particularly programmed death …